13.17
간질환이 약동학에 미치는 영향: 병태생리학적 평가 및 간기능 검사
임상에서 간기능을 평가하기 위해 간 혈류량을 직접 측정하는 일은 절차가 매우 복잡하고 고도의 전문 기술을 요구하므로 임상 적용이 어렵습니다. 이에 따라 의료진은 진찰과 간기능 검사로부터 얻은 경험적 추정값에 의존하여 간 기능 상태를 평가하는 경우가 많습니다. 간기능장애…
임상 실습에서 간 기능을 평가하기 위해 간 혈류를 직접 측정하는 것은 필요한 전문 기술로 인해 실용적이지 않은 경우가 많습니다.
대신 임상의는 환자 검사와 간 기능 검사를 통해 간 기능을 추정합니다.
Child-Pugh 및 MELD는 간 장애를 평가하는 데 도움이 되지만 약물 약동학과 직접적인 상관관계는 없습니다.
만성 간 질환은 약물 대사 및 제거에 영향을 미치므로 투약 전에 맞춤형 위험 평가가 필요합니다.
간 장애 환자에 대한 투약은 여전히 지속적인 개발 영역입니다. 그러나 아미노전이효소, 알칼리성 포스파타제, 빌리루빈 및 프로트롬빈 시간과 같은 약물 마커는 간 기능에 대한 귀중한 통찰력을 제공합니다.
예를 들어, AST/ALT 비율이 상승하면 급성 간 손상, 알코올성 간염 또는 진행성 간 섬유증을 나타내는 반면, AP 수치가 증가하면 간 종양 또는 담도 폐쇄를 나타낼 수 있습니다.
또한, 소변 빌리루빈 수치와 프로트롬빈 시간의 편차는 각각 간담도 질환과 간부전을 진단하는 데 도움이 될 수 있습니다.
View the full transcript and gain access to JoVE Core videos
Q1: Why can't clinicians directly measure hepatic blood flow to assess liver function?
Direct measurement of hepatic blood flow requires specialized techniques that are often impractical in clinical settings. Instead, clinicians estimate hepatic function through patient examination and liver function tests, which provide more accessible and reliable information for assessing drug metabolism and clearance in patients with liver disease.
Q2: What do the Child-Pugh and MELD scores tell us about drug pharmacokinetics?
While the Child-Pugh and MELD scoring systems effectively categorize hepatic impairment severity, they do not directly correlate with drug pharmacokinetics. These scores assess liver function but don't reliably predict how drugs will be metabolized or cleared in hepatically impaired patients, necessitating additional assessment for dosing decisions.
Q3: How do elevated AST and ALT ratios help diagnose liver disease?
Elevated AST/ALT ratios indicate acute liver injury, alcoholic hepatitis, or advanced liver fibrosis. These aminotransferase markers provide valuable insights into hepatic function and the liver's capacity to metabolize drugs, helping clinicians assess the degree of hepatic impairment and adjust medication dosing accordingly.
Q4: What does increased alkaline phosphatase suggest about liver health?
Increased alkaline phosphatase levels may indicate hepatic tumors or biliary obstruction, signaling potential compromise in liver function. This marker helps clinicians identify structural or metabolic abnormalities affecting the liver's ability to clear drugs and maintain functional capacity in patients requiring medication adjustments.
Q5: How do prothrombin time and urinary bilirubin levels differ in assessing hepatic disease?
Prothrombin time deviations signal hepatic failure or biliary obstruction by reflecting the liver's synthetic function, while variations in urinary bilirubin levels help diagnose hepatobiliary disease. Together, these markers provide complementary information about liver dysfunction and guide effect of hepatic disease on pharmacokinetics dose adjustments due to hepatic impairment.
Q6: Why does chronic liver disease require different dosing approaches than acute hepatitis?
Chronic liver disease significantly compromises drug metabolism and clearance, requiring systematic dosing adjustments. Acute hepatitis causes more nuanced metabolic changes, necessitating case-by-case assessment. Both conditions demand tailored risk evaluation before dosing, though establishing standardized guidelines for hepatically impaired patients remains an evolving area of clinical practice.
Q7: What role do liver function tests play in medication management for hepatic impairment?
Liver function tests measuring aminotransferases, alkaline phosphatase, bilirubin, and prothrombin time provide critical insights into hepatic function and drug clearance capacity. These markers enable clinicians to make informed decisions about tailored therapeutic interventions and medication adjustments, ensuring safe and effective treatment in patients with hepatic disease.